Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel acquired 1,000 shares of the stock in a transaction on Friday, December 16th. The shares were acquired at an average price of $13.01 per share, with a total value of $13,010.00. Following the purchase, the chief executive officer now owns 2,725,886 shares in the company, valued at $35,463,776.86. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Friday, December 9th, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $13.11 per share, with a total value of $26,220.00.
• On Friday, December 2nd, Snehal Patel purchased 1,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $13.84 per share, for a total transaction of $13,840.00.
• On Wednesday, November 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $8.79 per share, with a total value of $17,580.00.
• On Friday, October 14th, Snehal Patel purchased 3,000 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $9.75 per share, for a total transaction of $29,250.00.
• On Friday, October 7th, Snehal Patel acquired 2,000 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $9.72 per share, for a total transaction of $19,440.00.
• On Friday, October 7th, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $9.72 per share, for a total transaction of $19,440.00.
• On Thursday, September 29th, Snehal Patel acquired 1,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $9.23 per share, with a total value of $9,230.00.

Greenwich LifeSciences Stock Performance

Shares of NASDAQ:GLSI opened at $12.30 on Tuesday. Greenwich LifeSciences, Inc. has a 1-year low of $6.82 and a 1-year high of $30.36. The company's fifty day moving average is $11.16 and its two-hundred day moving average is $9.81. The stock has a market capitalization of $157.74 million, a price-to-earnings ratio of -21.58 and a beta of 0.81.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Greenwich LifeSciences by 150.2% in the first quarter. Vanguard Group Inc. now owns 375,200 shares of the company's stock worth $7,362,000 after buying an additional 225,213 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth about $891,000. Millennium Management LLC bought a new stake in Greenwich LifeSciences in the 2nd quarter valued at about $765,000. Occudo Quantitative Strategies LP bought a new position in Greenwich LifeSciences in the 2nd quarter worth about $199,000. Finally, Pura Vida Investments LLC acquired a new stake in shares of Greenwich LifeSciences in the third quarter valued at approximately $179,000. Institutional investors and hedge funds own 8.06% of the company's stock.

About Greenwich LifeSciences

(Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Recommended Stories

• Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
• Will Tesla Shares Rally If Musk Steps Down From Twitter?
• 5 Down But Not Out Stocks To Watch For 2023
• Can Chewy Fetch Double Digit Gains in 2023?
• Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
• Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.